NCT03368625 (NASRS) is a NA clinical trial of Stereotactic Radiosurgery in Brain Metastases, sponsored by University Health Network, Toronto.

Who is sponsoring NCT03368625?

NCT03368625 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT03368625?

Interventions in NCT03368625: Stereotactic Radiosurgery.

What condition does NCT03368625 study?

NCT03368625 studies Brain Metastases.

Is NCT03368625 still recruiting?

NCT03368625 is currently completed. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT03368625: NASRS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases

Completed NA Last updated 4 March 2026

What this trial tests

NA trial testing Stereotactic Radiosurgery in Brain Metastases in 30 participants. Completed in 10 October 2025.

Timeline

19 March 2018

Primary endpoint
10 October 2025

10 October 2025

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	19 March 2018
Primary completion	10 October 2025
Estimated completion	10 October 2025
Sites	2 locations across Canada, Germany

Drugs / interventions tested

Stereotactic Radiosurgery

Conditions studied

Brain Metastases — all drugs for Brain Metastases →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be a non-randomized phase II trial for patients with one to six brain metastases, at least one of which is appropriate for surgical resection. Upon registration, patients will be assigned to receive neo-adjuvant stereotactic radiosurgery (NASRS).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Treatment strategies for breast cancer brain metastases.
Bailleux C, Eberst L, Bachelot T. · · 2021 · cited 170× · PMID 33250512 · DOI 10.1038/s41416-020-01175-y
Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial.
Churilla TM, Chowdhury IH, Handorf E, Collette L, et al · · 2019 · cited 79× · PMID 30419088 · DOI 10.1001/jamaoncol.2018.4610
Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives.
Watase C, Shiino S, Shimoi T, Noguchi E, et al · · 2021 · cited 68× · PMID 33802424 · DOI 10.3390/cancers13051078
Operative and peri-operative considerations in the management of brain metastasis.
Sankey EW, Tsvankin V, Grabowski MM, Nayar G, et al · · 2019 · cited 31× · PMID 31568689 · DOI 10.1002/cam4.2577
Advances in the Management of Central Nervous System Metastases from Breast Cancer.
Avila J, Leone JP. · · 2022 · cited 6× · PMID 36293379 · DOI 10.3390/ijms232012525
Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells.
Hintelmann K, Petersen C, Borgmann K. · · 2022 · cited 5× · PMID 36612206 · DOI 10.3390/cancers15010211
What if: A retrospective reconstruction of resection cavity stereotactic radiosurgery to mimic neoadjuvant stereotactic radiosurgery.
Acker G, Nachbar M, Soffried N, Bodnar B, et al · · 2023 · cited 4× · PMID 37007157 · DOI 10.3389/fonc.2023.1056330
Neurosurgical Interventions for Cerebral Metastases of Solid Tumors.
Thon N, Karschnia P, von Baumgarten L, Niyazi M, et al · · 2023 · cited 3× · PMID 36650742 · DOI 10.3238/arztebl.m2022.0410

Verify or expand the search:

Other trials of Stereotactic Radiosurgery

Trials testing the same drug.

NCT06649058 — EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study · Phase 2 · recruiting
NCT06287515 — Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain · Phase 1 · recruiting
NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting
NCT06204315 — Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compres · Phase 2 · recruiting
NCT06248606 — Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases · Phase 2 · recruiting

Other recruiting trials for Brain Metastases

Currently open trials in the same condition.

NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
NCT07227610 — Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) · Phase 2 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03368625 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03368625.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing